影响慢性乙型肝炎肝纤维化逆转因素的新进展

摘要/Abstract

摘要： 肝纤维化逆转可阻断并改善慢性乙型肝炎肝纤维化患者的临床结局。然而,部分患者即使经过持续抗病毒治疗,其肝纤维化仍无法逆转甚至出现进展。已有系列研究发现,低病毒血症、脂肪变性、酒精摄入和丁型肝炎病毒共感染等因素均可阻碍纤维化逆转。

吴思儒, 陈姝延, 尤红. 影响慢性乙型肝炎肝纤维化逆转因素的新进展[J]. 肝脏, 2026, 31(6): 905-908.

/ 推荐

[1] 陆伦根, 尤红, 谢渭芬, 等. 肝纤维化诊断及治疗共识(2019年)[J]. 实用肝脏病杂志, 2019, 22(6): 793-803.
[2] Marcellin P, Gane E, Buti M, et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study[J]. The Lancet, 2013, 381(9865): 468-475.
[3] Liaw Y F, Sung J J, Chow W C, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease[J]. N Engl J Med, 2004, 351(15): 1521-1531.
[4] Zoutendijk R, Reijnders J G, Zoulim F, et al. Virological response to entecavir is associated with a better clinical outcome in chronic hepatitis B patients with cirrhosis[J]. Gut, 2013, 62(5): 760-765.
[5] Chon H Y, Ahn S H, Kim Y J, et al. Efficacy of entecavir, tenofovir disoproxil fumarate, and tenofovir alafenamide in treatment-naive hepatitis B patients[J]. Hepatol Int, 2021, 15(6): 1328-1336.
[6] Chen S, Zhou J, Wu X, et al. Liver fibrosis showed a two-phase regression rate during long-term anti-HBV therapy by three-time biopsies assessments[J]. Hepatol Int, 2024, 18 (3): 904-916.
[7] Sun Y, Chen W, Chen S, et al. Regression of liver fibrosis in patients on hepatitis B therapy is associated with decreased liver-related events[J]. Clin Gastroenterol Hepatol, 2024, 22(3): 591-601.
[8] Sun Y, Zhou J, Wang L, et al. New classification of liver biopsy assessment for fibrosis in chronic hepatitis B patients before and after treatment[J]. Hepatology, 2017, 65(5): 1438-1450.
[9] Terrault N, Lok A, McMahon B, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance[J]. Hepatology, 2018, 67(4): 1560-1599.
[10] 鲁凤民, 封波, 郑素军, 等.核苷(酸)类似物经治的慢性乙型肝炎患者低病毒血症的研究现状[J]. 临床肝胆病杂志, 2021, 37(6): 1268-1274.
[11] Sun Y, Wu X, Zhou J, et al. Persistent low level of hepatitis B virus promotes fibrosis progression during therapy[J]. Clin Gastroenterol Hepatol, 2020, 18(11): 2582-2591.
[12] Lu Z, Sun Y, Chen S, et al. Multiple low-level viremia suggest hindered liver fibrosis regression in chronic hepatitis B patients during antiviral therapy[J]. J Viral Hepat, 2024, 31(12): 898-902.
[13] Kim J, Sinn D, Kang W, et al. Low-level viremia and the increased risk of hepatocellular carcinoma in patients receiving entecavir treatment[J]. Hepatology, 2017, 66(2): 335-343.
[14] Allweiss L, Dandri M. The role of cccDNA in HBV maintenance[J]. Viruses, 2017, 9(6): 156.
[15] Werle-Lapostolle B, Bowden S, Locarnini S, et al. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy[J]. Gastroenterology, 2004, 126(7): 1750-1758.
[16] Dandri M, Burda M R, Will H, et al. Increased hepatocyte turnover and inhibition of woodchuck hepatitis B virus replication by adefovir in vitro do not lead to reduction of the closed circular DNA[J]. Hepatology, 2000, 32(1): 139-146.
[17] Bowden S, Locarnini S, Chang T T, et al. Covalently closed-circular hepatitis B virus DNA reduction with entecavir or lamivudine[J]. World J Gastroenterol, 2015, 21(15): 4644-4651.
[18] Zheng Q, Zou B, Wu Y, et al. Systematic review with meta-analysis: prevalence of hepatic steatosis, fibrosis and associated factors in chronic hepatitis B[J]. Aliment Pharmacol Ther, 2021, 54(9): 1100-1109.
[19] Hui R W H, Seto W K, Cheung K S, et al. Inverse relationship between hepatic steatosis and hepatitis B viremia: results of a large case-control study[J]. J Viral Hepat, 2018, 25(1): 97-104.
[20] Shi J, Fan J, Wu R, et al. Prevalence and risk factors of hepatic steatosis and its impact on liver injury in Chinese patients with chronic hepatitis B infection[J]. J Gastroenterol Hepatol, 2008, 23(9): 1419-1425.
[21] Mak L Y, Hui R W H, Fung J, et al. Diverse effects of hepatic steatosis on fibrosis progression and functional cure in virologically quiescent chronic hepatitis B[J]. J Hepatol, 2020, 73(4): 800-806.
[22] Zhang M, Chen S, Wu X, et al. Persistent steatosis correlates with decreased fibrosis regression during anti-HBV treatment in patients with chronic HBV infection[J]. J Med Virol, 2023, 95(10): e29156.
[23] Mak L Y, Hui R W H, Fung J, et al. Reduced hepatic steatosis is associated with higher risk of hepatocellular carcinoma in chronic hepatitis B infection[J]. Hepatol Int, 2021, 15(4): 901-911.
[24] Li J, Yang H I, Yeh M L, et al. Association between fatty liver and cirrhosis, hepatocellular carcinoma, and hepatitis B surface antigen seroclearance in chronic hepatitis B[J]. J Infect Dis, 2021, 224(2): 294-302.
[25] Van Kleef L A, Choi H S J, Brouwer W P, et al. Metabolic dysfunction-associated fatty liver disease increases risk of adverse outcomes in patients with chronic hepatitis B[J]. JHEP Rep, 2021, 3(5): 100350.
[26] Mao X, Cheung K S, Peng C, et al. Steatosis, HBV-related HCC, cirrhosis, and HBsAg seroclearance: a systematic review and meta-analysis[J]. Hepatology, 2023, 77(5): 1735.
[27] Louvet A, Mathurin P. Alcoholic liver disease: mechanisms of injury and targeted treatment[J]. Nat Rev Gastroenterol Hepatol, 2015, 12(4): 231-242.
[28] Seitz H K, Bataller R, Cortez-Pino H, et al. Alcoholic liver disease[J]. Nat Rev Dis Primers, 2018, 4(1): 17.
[29] O′Shea R S, Dasarathy S, McCullough A J, et al. Alcoholic liver disease[J]. Hepatology, 2010, 51(1): 307-328.
[30] Martino C, Zaramela L S, Gao B, et al. Acetate reprograms gut microbiota during alcohol consumption[J]. Nat Commun, 2022, 13(1): 4630.
[31] Chung W G, Kim H J, Choe Y G, et al. Clinical impacts of hazardous alcohol use and obesity on the outcome of entecavir therapy in treatment-naïve patients with chronic hepatitis B infection[J]. Clin Mol Hepatol, 2012, 18(2): 195.
[32] Hur M H, Yip T C F, Kim S U, et al. A machine learning model to predict liver-related outcomes after the functional cure of chronic hepatitis B[J]. J Hepatol, 2025, 82(2): 235-244
[33] Zaborska V O, Ko H H, MacIsaac J, et al. Clinical characteristics and prevalence of hepatitis delta virus (HDV) infected individuals in British Columbia and Ontario: a multi-centre update[C]. 2024 AASLD Annual Meeting, Nov 15-19, 2024. San Diego, California, American Association for the Study of Liver Diseases. S134-S135.
[34] Xu H, Lin S, Yang L, et al. Recent seroprevalence and epidemiological characteristics of HDV infection among HBsAg-positive inpatients in China[C]. 2024 AASLD Annual Meeting, Nov 15-19, 2024. San Diego, California, American Association for the Study of Liver Diseases. S116-S117.
[35] Roulot D, Brichler S, Layese R, et al. Origin, HDV genotype and persistent viremia determine outcome and treatment response in patients with chronic hepatitis delta[J]. J Hepatol, 2020, 73(5): 1046-1062.
[36] Alfaiate D. Chronic hepatitis D and hepatocellular carcinoma: a systematic review and meta-analysis of observational studies[J]. J Hepatol, 2020, 73(3): 533-539.
[37] Wranke A, Serrano B C, Heidrich B, et al. Antiviral treatment and liver-related complications in hepatitis delta[J]. Hepatology, 2017, 65(2): 414-425.
[38] Wanless I R, Nakashima E, Sherman M. Regression of human cirrhosis. Morphologic features and the genesis of incomplete septal cirrhosis[J]. Arch Pathol Lab Med, 2000, 124(11): 1599-1607.
[39] Bedossa P. Reversibility of hepatitis B virus cirrhosis after therapy: who and why?[J]. Liver Int, 2015, 35(Suppl 1): 78-81.
[40] Chen S, Wang B, Zhou J, et al. A new glutamine synthetase index to evaluate hepatic lobular restoration in advanced fibrosis during anti-HBV therapy[J]. J Med Virol, 2023, 95(2): e28555.

影响慢性乙型肝炎肝纤维化逆转因素的新进展

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	徐璐, 芮法娟, 胡新玉, 李婕. 代谢相关脂肪性肝病进展综合防控策略[J]. 肝脏, 2026, 31(6): 778-786.
[2]	张丽丽, 王韶华, 胡建华. 国内肝纤维化临床注册现状[J]. 肝脏, 2026, 31(6): 842-846.
[3]	赵英超, 罗朵朵, 武湘华, 任育慧, 王艳, 强晓辉, 杜海峰. 剪切波弹性成像联合APRI诊断酒精性肝病患者肝纤维化程度的价值[J]. 肝脏, 2026, 31(6): 847-850.
[4]	刘小兰, 王体伟. 乙型肝炎肝纤维化声像和弹性成像特征分析及其在疾病诊断和病情评估中的价值[J]. 肝脏, 2026, 31(6): 851-856.
[5]	张雪棉, 刘文钏, 武云慧. 超声组织结构声学定量分析评估慢性乙型肝炎患者肝纤维化严重程度的价值[J]. 肝脏, 2026, 31(6): 857-862.
[6]	许城英, 孙璐, 毛成洁, 王敏英, 陆忠华. 血清Ⅳ型胶原相对值及其组合模型在代谢相关脂肪性肝病肝脏炎症与纤维化评估中的应用价值[J]. 肝脏, 2026, 31(6): 886-890.
[7]	王建鲁, 孙剑, 申笙. 基于HBeAg与HBsAg定量的HBV相关肝癌风险精准分层[J]. 肝脏, 2026, 31(5): 599-602.
[8]	朱坤, 刘牧云. 儿童代谢功能障碍相关脂肪性肝病的疾病负担与远期结局[J]. 肝脏, 2026, 31(5): 609-615.
[9]	曾华礼, 施迎迎, 高晓雯, 吕海明. 慢性乙型肝炎患者血清CC类趋化因子配体5水平与肝纤维化的关系[J]. 肝脏, 2026, 31(5): 625-630.
[10]	金业森, 杨广越, 陶乐, 吴柳, 叶军, 马文婷. 血清HBV RNA对ALT正常慢性乙型肝炎患者HBeAg血清学转换的预测作用[J]. 肝脏, 2026, 31(5): 631-634.
[11]	胡艳蓉, 陆佳赟, 孙舒, 尤虹, 钱先中. 恩替卡韦与替诺福韦酯治疗ALT正常慢性乙型肝炎患者的疗效与安全性比较[J]. 肝脏, 2026, 31(5): 635-638.
[12]	刘云霄, 张荣, 王晓忠. 高血压与2型糖尿病对代谢功能障碍相关脂肪性肝病肝纤维化的交互作用分析[J]. 肝脏, 2026, 31(5): 673-677.
[13]	苗瑞田, 刘敏, 周赟, 刘春芳. 老年非酒精性脂肪性肝病患者进展为显著肝纤维化的危险因素观察[J]. 肝脏, 2026, 31(5): 687-692.
[14]	张思雨, 朱质斌, 陈军. 慢性乙型肝炎与骨质疏松症[J]. 肝脏, 2026, 31(4): 474-476.
[15]	黄菲, 何双媚, 秦春俊, 杨静仪, 满银雪. NAs治疗应答不佳的慢性乙型肝炎患者转用干扰素α-2b的临床疗效[J]. 肝脏, 2026, 31(4): 486-489.